Herbst K D, Rapaport S I, Kenoyer D G, Stanton W, Feinstein D I
Ann Intern Med. 1981 Nov;95(5):575-8. doi: 10.7326/0003-4819-95-5-575.
Six patients with an acquired inhibitor of factor VIII had the following clinical characteristics: older age group; absence of definable, underlying disease; a low titer of the factor VIII inhibitor; notable residual plasma factor VIII activity despite the inhibitor; serious bleeding not controlled by infusion of factor VIII; and disappearance of the inhibitor after treatment with cyclophosphamide and prednisone. These findings delineate a syndrome characteristic of a subset of patients with an acquired factor VIII inhibitor. It is important to emphasize that such patients may bleed uncontrollably despite the misleading presence of residual plasma factor VIII activity in vitro, and that the inhibitor disappears after immunosuppressive therapy. Thus, we believe that patients with this syndrome should be treated with cyclophosphamide and prednisone as soon as the inhibitor is identified.
6例获得性Ⅷ因子抑制物患者具有以下临床特征:年龄较大;无明确的基础疾病;Ⅷ因子抑制物滴度较低;尽管存在抑制物,但血浆Ⅷ因子仍有显著残余活性;输注Ⅷ因子无法控制严重出血;环磷酰胺和泼尼松治疗后抑制物消失。这些发现描绘了获得性Ⅷ因子抑制物患者亚组的一种特征性综合征。必须强调的是,尽管体外存在误导性的血浆Ⅷ因子残余活性,但这类患者仍可能发生无法控制的出血,且免疫抑制治疗后抑制物会消失。因此,我们认为一旦确诊该综合征,患者应立即接受环磷酰胺和泼尼松治疗。